Streetbeat News

Products Services

CDT

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has announced a partnership with ClinConnect to conduct a cocrystal development program for its AZD1656 compound, a molecule with potential treatment applications in various autoimmune disorders. The program aims to improve the solubility, stability, and bioavailability of AZD1656. Conduit, which went public in September 2023, acquires assets that have undergone some pre-clinical and clinical testing and works to accelerate them through Phase II trials.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:45 pm

AAPL

A survey by investment firm Piper Sandler reveals that Apple Inc.'s iPhones continue to be popular among American teenagers, with 87% of them owning an iPhone and 88% expecting it to be their next phone. The Apple Watch has also gained traction among teenagers, with 34% owning one. However, enthusiasm for purchasing a new Apple Watch in the next six months has dipped to 10%, down from 16% the previous year.

Portfolio Pulse from Rounak Jain

October 11, 2023 | 12:43 pm

NVO

PHIO

TPST

Tempest Therapeutics (TPST) released new data showing superiority of TPST-1120 across multiple study endpoints, causing a 440% increase in its stock. Phio Pharmaceuticals (PHIO) presented new data for targeting BRD4 with its INTASYL™ Compound PH-894, leading to a 77% increase in its stock. Novo Nordisk (NVO) shares rose by 5.3% after the independent Data Monitoring Committee recommended to stop semaglutide FLOW kidney trial due to signs of early efficacy.

Portfolio Pulse from ryanfaloona@benzinga.com

October 11, 2023 | 12:42 pm

CDTX

Cidara Therapeutics has presented new preclinical and clinical data on its novel drug-Fc conjugate CD388 at IDWeek 2023.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:42 pm

YTEN

Yield10 Bioscience, Inc. (NASDAQ:YTEN) has announced advancements in the development of herbicide tolerant Camelina, a crop used for production of low-carbon intensity feedstock oil for the biofuel market. The company is on track for a commercial launch of the first herbicide tolerant Camelina variety as early as 2025. Yield10 is also developing an herbicide package for Camelina, incorporating tolerance to broadleaf herbicide and soil residual Group 2 herbicides. The company has filed a request for Regulatory Status Review with USDA-APHIS Biotechnology Regulatory Services for its herbicide tolerant Camelina.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:41 pm

RLMD

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced new preclinical data on its novel psilocybin, showing significant reductions in liver fat content, plasma glucose levels, and body weight gain in a mice model. The company plans to initiate a single-ascending dose Phase 1 trial in patients in early 2024. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:41 pm

SLS

SELLAS Life Sciences Group, Inc. has announced that the first patient has been dosed in a Phase Ib/II trial of SLS009 (GFH009) in relapsed/refractory peripheral T-cell lymphomas. This marks a significant step in the development of the drug.

Portfolio Pulse from Bill Haddad

October 11, 2023 | 12:41 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc, and Discord Inc have been hosting a chat for users of Bard, Google's AI-powered chatbot. There are concerns about the reliability of large language models (LLMs) like Bard, and the need for independent verification of their outputs. Users have raised concerns about Bard generating inaccurate information and potentially hazardous advice. Google has introduced a search button on Bard to allow users to validate the AI-generated responses. The success of Bard is crucial for Google as generative AI technologies threaten Google's dominance in the search market.

Portfolio Pulse from Anusuya Lahiri

October 11, 2023 | 12:40 pm

LH

Labcorp (NYSE:LH) has launched a new blood-based test, the ATN Profile, to accelerate the diagnosis of Alzheimer's disease. The test uses three blood biomarkers to detect the hallmarks of Alzheimer's disease. It is available through physicians for patients being evaluated for possible Alzheimer's disease or other cognitive impairments. The ATN Profile is expected to support more informed decision-making and improved personalized patient care.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:39 pm

HYLN

Hyliion Holdings Corp (HYLN) shares have dropped by 35.9% following the company's announcement that it is exploring strategic options for its powertrain business due to slow market adoption and regulatory compliance needs. The company will continue commercializing the KARNO generator but will pause efforts like securing orders for their Hypertruck ERX and new powertrain development work. A conference call to discuss this strategic review will be held on October 11.

Portfolio Pulse from Henry Khederian

October 11, 2023 | 12:39 pm